98300-40-4

Basic information

• Product Name: 1-(2,3-Dimethoxy-6-nitrophenyl)ethanone
• Synonyms: 1-(2,3-Dimethoxy-6-nitrophenyl)ethanone
• CAS NO: 98300-40-4
• Molecular Weight: 225.201
• Mol File: 98300-40-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-(2,3-Dimethoxy-6-nitrophenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,3-Dimethoxy-6-nitrophenyl)ethanone(98300-40-4)
• EPA Substance Registry System: 1-(2,3-Dimethoxy-6-nitrophenyl)ethanone(98300-40-4)

Safety Data

• Hazardous Substances Data: 98300-40-4(Hazardous Substances Data)

Usage

Description

1-(2,3-Dimethoxy-6-nitrophenyl)ethanone is a chemical compound characterized by its molecular formula C10H11NO5. It presents as a yellow to orange crystalline powder with a molecular weight of 225.2 g/mol. 1-(2,3-Dimethoxy-6-nitrophenyl)ethanone is recognized for its role as a building block in the synthesis of various organic compounds, particularly those with biological and pharmacological activities. Its unique structure and properties make it a promising candidate for the development of drugs and other pharmaceutical products.

Uses

Used in Organic Synthesis:
1-(2,3-Dimethoxy-6-nitrophenyl)ethanone is used as a key intermediate for the synthesis of complex organic molecules. Its presence in the synthesis process allows for the creation of a wide range of compounds with diverse applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(2,3-Dimethoxy-6-nitrophenyl)ethanone is utilized as a valuable component in drug development. Its unique properties contribute to the formulation of new drugs and pharmaceutical products, potentially leading to advancements in medicine.
Used in the Development of Drugs:
Due to its potential biological and pharmacological activities, 1-(2,3-Dimethoxy-6-nitrophenyl)ethanone is employed as a precursor in the development of new drugs. Its integration into drug molecules can enhance their efficacy and contribute to the treatment of various medical conditions.

Upstream product

• 98263-19-5 2,3-dimethoxy-6-nitrobenzoyl chloride 
• 72517-26-1 2,3-dimethoxy-6-nitrobenzoic acid 
• 103483-20-1 diethyl 2-(2,3-dimethoxy-6-nitrobenzoyl)-propanedioate 
• 38480-94-3 2,3-dimethoxyacetophenone 
• 5653-62-3 2,3-dimethoxybenzonitrile 
• 111042-36-5 2-Hydroxy-3-methoxy-6-nitrobenzaldehyde, sodium salt 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 
• 2426-60-0 2-Hydroxy-3-methoxy-6-nitrobenzaldehyde benzenesulfonate 
• 2426-85-9 2-Hydroxy-3-methoxybenzaldehyde benzenesulfonate 
• 2531-63-7 5,6-dimethoxy-2-nitrobenzaldehyde 

Downstream Products

• 1256037-05-4 N-(2-acetyl-3,4-dimethoxyphenyl)-2-fluorobenzamide 
• 1256037-23-6 2-(2-fluorophenyl)-5,6-dimethoxyquinolin-4-one 
• 1256037-40-7 2-(2-fluorophenyl)-5-hydroxy-6-methoxyquinolin-4-one 
• 103483-21-2 6-Carboethoxyamino-2,3-dimethoxyacetophenone 
• 92210-43-0 5,6-dimethoxy-4-methyl-2(1H)-quinazolinone 
• 98300-41-5 6'-amino-2',3'-dimethoxyacetophenone 

Relevant articles and documents

SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES

A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH)2, P(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, P(═O)(OH)(OM), P(═O)(OM)2, P═O(O2M), S(═O)(OH)2, S(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, S(═O)(OH)(OM), S(═O)(OM)2; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C6-C20)aryl, (C6-C20)heteroaryl, (C1-C18)alkyl(C6-C20)aryl, (C1-C18)alkyl(C6-C20)heteroaryl, hydroxy(C6-C20)aryl, hydroxy(C6-C20)heteroaryl, (C1-C18)alkoxy(C6-C20)aryl, (C1-C18)alkoxy(C6-C20)heteroaryl, (C1-C18)alkylenedioxy(C6-C20)aryl, (C1-C18)alkylenedioxy(C6-C20)heteroaryl, halo(C6-C20)aryl, halo(C6-C20)heteroaryl, (C1-C18)alkylamino(C6-C20)aryl, (C1-C18)alkylamino(C6-C20)heteroaryl, (C1-C18)cycloalkylamino(C6-C20)aryl, or (C1-C18)cycloalkylamino(C6-C20)heteroaryl, and their OR8 substutes; R5 is (C1-C18alkoxy, hydrogen, hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or OR8, or R5 and R6 are (C1-C18)dioxy provided that R7 is hydrogen; R6 is hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or ORR, (C1-C18)alkoxy, (C1-C18)alkylamino, or (C1-C18)cycloalkylamino, or R6 and R7 are (C1-C18)dioxy provided that R5 is hydrogen; R7 is hydrogen, halo or OR8, hydroxyl, or O—(C1-C18)alkyl(C6-C20)aryl; and R8 is P(═O)(OH)2, P(═O)(O(C1-C18)alkyl(C6-C20)aryl)2, P(═O)(OH)(OM), or P(═O)(OM)2, P═O(O2M).

Synthesis and Cardiotonic Activity of a Series of Substituted 4-Alkyl-2(1H)-quinazolinones

The synthesis, cardiac fraction III cyclic nucleotide phosphodiesterase (PDE-III) inhibition, and positive inotropic activity of a series of 2(1H)-quinazolinones are reported.A general synthesis of the series involved the cyclization of 2-aminoacetophenones with potassium cyanate in acetic acid.Modifications at the 4-position of the quinazoline nucleus were best achieved by formation of the intermediate N1-acyl-N3-phenylurea from the substituted phenyl isocyanate and appropriate carboxamide.PPA was used to ring close to the quinazoline product.Generally the SAR for the series paralleled the five-point model previously published for PDE-III inhibition.The most active analogue of the series was 5,6-dimethoxy-4-methyl-2(1H)-quinazolinone (1) (ORF 16600), which had about twice the intravenous potency of amrinone.Compound 1 is currently under development as an orally active cardiotonic.

3,4-Dialkoxy-2-alkylcarbonyl analino compounds

A process for preparing 4-alkyl-2(1H)quinazolinone-1-alkanoic acid derivatives is described. The 4-alkyl-2(1H)quinazolinones are useful as cardiovascular agents.